Percutaneous mitral annuloplasty using a coronary sinus device reduced mitral regurgitation from 3-4+ to 0-1+ (P<0.03) and decreased septal-lateral annular diameter in an ovine model.
Does a percutaneous transvenous coronary sinus annuloplasty device reduce mitral regurgitation in an ovine model of acute ischemic MR?
Percutaneous transvenous coronary sinus annuloplasty is feasible and acutely reduces ischemic mitral regurgitation in an ovine model.
p-value: p=< 0.03
Annuloplasty is the cornerstone of surgical mitral valve repair. A percutaneous transvenous catheter-based approach for mitral valve repair was tested by placing a novel annuloplasty device in the coronary sinus of sheep with acute ischemic mitral regurgitation. Mitral regurgitation was reduced from 3-4+ to 0-1+ in all animals (P < 0.03). The annuloplasty functioned by reducing septal-lateral mitral annular diameter (30 +/- 2.1 mm preinsertion vs. 24 +/- 1.7 mm postinsertion; P < 0.03). These preliminary experiments demonstrate that percutaneous mitral annuloplasty is feasible. Further study is necessary to demonstrate long-term safety and efficacy of this novel approach.
Liddicoat et al. (Wed,) conducted a other in Acute ischemic mitral regurgitation. Percutaneous transvenous catheter-based annuloplasty device vs. Pre-insertion (baseline) was evaluated on Mitral regurgitation severity and septal-lateral mitral annular diameter (p=< 0.03). Percutaneous mitral annuloplasty using a coronary sinus device reduced mitral regurgitation from 3-4+ to 0-1+ (P<0.03) and decreased septal-lateral annular diameter in an ovine model.